Last week, AcelRx Pharmaceuticals (NASDAQ:ACRX) presented results from its Phase 3 SAP302 trial for its pipeline drug ARX-04, designed to treat patients suffering …
In a research report released Monday, H.C.
Roth Capital analyst Ed Arce maintained a Buy rating on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a $20 price target, following the news that the FDA …
In a research report published Friday, Roth Capital analyst Ed Arce reiterated a Buy rating on Conatus Pharmaceuticals (NASDAQ:CNAT), but reduced his price …
Roth Capital healthcare analyst Ed Arce is out today with some bullish thoughts on Cempra (NASDAQ:CEMP), initiating shares with a Buy rating and a $35 price …
In a research report issued today, Roth Capital analyst Ed Arce reiterated a Buy rating on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a $20 price target, …
Roth Capital analyst Ed Arce reiterated a Buy rating on Conatus Pharmaceuticals (NASDAQ:CNAT) with a price target of $19, which represents a potential …
Roth Capital analyst Ed Arce reiterated a Buy rating on Xoma (NASDAQ:XOMA) with a $9 price target, which represents a potential upside of 127% …
Roth Capital analyst Ed Arce is out with his second note this week on Acelrx Pharmaceuticals (NASDAQ:ACRX) maintaining a Neutral rating with a $6 price target, following …
Roth Capital analyst Ed Arce reaffirmed a Neutral rating on Acelrx Pharmaceuticals (NASDAQ:ACRX) with a $6 price target, as the company announced that CEO Richard …
